Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

Inclusion Criteria: * Informed consent available * \> 45 years of age * PDAC cases * Treatment-naïve, pathologically confirmed PDAC Stage I or Stage II * Sporadic or familial/genetic PDAC * Controls * Individuals at high risk for PDAC because of their familial and/or genetic history * Individuals at high risk for PDAC because of pancreatic cysts between 1.0cm and 3.0cm in diameter. * Controls will be selected to have similar demographic features (age/gender) to PDAC patients Exclusion Criteria: * Prior treatment for PDAC (i.e., prior resection, radiotherapy, or chemotherapy) * Current immunosuppressive (e.g., systemic steroid therapy) or chemotherapy * Major surgery or significant trauma within 12 weeks prior to blood sample collection * Non-PDAC malignancies within 3 years prior to sample collection squamous or basal cell skin carcinoma is not an exclusion criteria) * Control patients who currently have * biliary obstruction secondary to gallstones * prior diagnosis or imaging evidence of chronic pancreatitis * cystic pancreatic lesions \>3.0 cm in diameter or showing worrisome features according to Fukuoka Consensus Guidelines.